A Freya-28 recall has recently been issued in Canada for the popular birth control medication. The recent birth control recall is the third one in six months. The recall has alarmed Canadian women and has raised questions about the quality of the drug plants that produce the birth control products.
Why was the Freya-28 recall issued?
The Freya-28 recall was issued because some of the pills contained placebo instead of actual birth control medication. This extra placebo can lead to unwanted pregnancies by women who use this product. The plethora of problems with birth control pills, the newness of Freya-28 to the market, and the delays in communicating the birth control recalls are a cause for concern. Approximately 430,000 birth control products had been prescribed to Canadian women as of June.
Other Birth Control Recalls Issued
Along with Freya-28, another generic birth control product was recalled because of placebo pills found inside the package. Esme-28 is one of the generic birth control products that were recalled. The Esme-28 and Freya-28 recall were issued a week apart. Esme-28 and Freya-28 are both produced in the same Indian plant overseas. Health Canada has yet to deny the possibility that the mistake occurred during the packaging process. There has yet to be an explanation as to why both birth control products have not been removed from shelves as soon as the Freya-28 recall was issued.
Just last April, another recall was issued for Alysena birth control products because of a placebo pill found inside the bottle. It took several days before a public announcement was made about the recall. The federal health minister is looking into the delay of the public announcement of the recall.
Alysena, Esme, and Freya have all been in the market for a few months. According to IMS Brogan, a health-tracker, there have been approximately 3,600 prescriptions made for Esme birth control products, 6,200 prescriptions for Freya, and 419,800 prescriptions for Alysena, all of which are in Canada.
Rona Ambrose, Canada’s Health Minister has issued a statement stating that she is waiting for the results of the reviews conducted by government agencies. She is also expecting Health Canada and drug producers to inform the Canadian public about the risk of using such products.